Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Shifts Sales Focus To Crestor

This article was originally published in PharmAsia News

Executive Summary

Japan's Shionogi plans to step up its promotions in hospitals to create an 83 percent increase in domestic sales of its Crestor (rosuvastatin) cholesterol drug by next March. The company said it would train some of its 1,450 medical representatives to promote use of the drug in hospitals instead of only to clinics, and to track the frequency with which it is prescribed. The focus on the statin marks a shift by Shionogi away from anti-microbial agents and their declining sales to metabolic syndrome medicines. (Click here for more - a subscription may be required
Advertisement

Related Content

Shionogi Expects Crestor To Overtake Pfizer’s Lipitor
Advertisement
UsernamePublicRestriction

Register

SC068876

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel